«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 04

Page:

652-658

Research Field:

Publishing date:

Info

Title:

The relationship between peripheral haematological indicators and the efficacy of immune checkpoint inhibitors in the treatment of advanced non-small cell lung cancer

Author(s):

LIANG Jiaxin¹; ZHANG Guifang²; MU Zhuqing²; HUANG Puchao²; MA Xiaoyan²; LI Bin¹

1.Xinxiang Medical College,Henan Xinxiang 453000,China;2.Xinxiang Central Hospital,Henan Xinxiang 453000,China.

Keywords:

non-small cell lung cancer; immune checkpoint inhibitors; hematology; biomarkers

PACS:

R734.2

DOI:

10.3969/j.issn.1672-4992.2024.04.011

Abstract:

Objective:To observe the efficacy and adverse effects of immune checkpoint inhibitors (ICIs) treatment for advanced non-small cell lung cancer (NSCLC) in the real world,and to explore the relationship between peripheral haematological indices and the efficacy of ICIs.Methods:We retrospectively analysed the immune response,case characteristics and peripheral haematological indices in 95 advanced NSCLC patients who received immunotherapy in our hospital,and univariate and multivariate statistical analyses were performed for the objective immune response.Results:The objective response rate of the 95 enrolled patients was 32.63% (31/95) and the disease control rate was 70.53% (67/95).The median progression-free survival was 4.1 months and the median overall survival was 9.5 months.Univariate analysis showed that the number of lines of therapy (P=0.016),driver genes (P=0.018),lymphocyte percentage (P=0.036),haemoglobin (P=0.049),haematocrit (P=0.039),prothrombin time (P=0.021),albumin (P=0.002),precursor albumin (P=0.031),lactate dehydrogenase (P=0.001),C-reactive protein (P=0.028),PNI (P=0.004) were associated with whether the disease was effectively controlled after ICIs treatment.Multivariate analysis identified lymphocyte percentage (P=0.042),albumin (P=0.003),lactate dehydrogenase (P=0.006),prognostic nutritional index (P=0.029) and number of treatment lines (P=0.011) as independent factors influencing the efficacy of ICIs.Conclusion:Early treatment with ICIs resulted in improved survival benefit,and the percentage of peripheral lymphocytes,albumin,lactate dehydrogenase,PNI could be used as potential biomarkers for predicting the efficacy of ICIs.

References:

£Û1£Ý SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries£ÛJ£Ý.CA Cancer J Clin,2021,71(3):209-249.
£Û2£Ý MOLINA JR,YANG P,CASSIVI SD,et al.Non-small cell lung cancer:epidemiology,risk factors,treatment,and survivorship£ÛJ£Ý.Mayo Clin Proc,2008,83(5):584-594.
£Û3£Ý HERBST RS,MORGENSZTERN D,BOSHOFF C.The biology and management of non-small cell lung cancer£ÛJ£Ý.Nature,2018,553(7689):446-454.
£Û4£Ý BAGCHI S,YUAN R,ENGLEMAN EG.Immune checkpoint inhibitors for the treatment of cancer:clinical impact and mechanisms of response and resistance£ÛJ£Ý.Annu Rev Pathol,2021,16:223-249.
£Û5£Ý HELLMANN MD,PAZ-ARES L,BERNABE CARO R,et al.Nivolumab plus ipilimumab in advanced non-small-cell lung cancer£ÛJ£Ý.N Engl J Med,2019,381(21):2020-2031.
£Û6£Ý SOCINSKI MA,JOTTE RM,CAPPUZZO F,et al.Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC£ÛJ£Ý.N Engl J Med,2018,378(24):2288-2301.
£Û7£Ý PAZ-ARES L,LUFT A,VICENTE D,et al.Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer£ÛJ£Ý.N Engl J Med,2018,379(21):2040-2051.
£Û8£Ý GANDHI L,RODRIGUEZ-ABREU D,GADGEEL S,et al.Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer£ÛJ£Ý.N Engl J Med,2018,378(22):2078-2092.
£Û9£Ý MOK TSK,WU YL,KUDABA I,et al.Pembrolizumab versus chemotherapy for previously untreated,PD-L1-expressing,locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042):a randomised,open-label,controlled,phase 3 trial£ÛJ£Ý.Lancet,2019,393(10183):1819-1830.
£Û10£Ý HERBST RS,BAAS P,KIM DW,et al.Pembrolizumab versus docetaxel for previously treated,PD-L1-positive,advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial£ÛJ£Ý.Lancet,2016,387(10027):1540-1550.
£Û11£Ý HEGDE PS,CHEN DS.Top 10 challenges in cancer immunotherapy£ÛJ£Ý.Immunity,2020,52(1):17-35.
£Û12£Ý SEYMOUR L,BOGAERTS J,PERRONE A,et al.iRECIST:guidelines for response criteria for use in trials testing immunotherapeutics£ÛJ£Ý.Lancet Oncol,2017,18(3):e143-e152.
£Û13£Ý BETHESDA MD,National Cancer Institute.Common terminology criteria for adverse events (CTCAE) (version 5.0)£ÛJ/OL£Ý.National Institutes of Health Publication£Û£²£°£±£·ª²£±£±ª²£²£·£Ý.https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
£Û14£Ý RECK M,REMON J,HELLMANN MD.First-line immunotherapy for non-small-cell lung cancer£ÛJ£Ý.J Clin Oncol,2022,40(6):586-597.
£Û15£Ý ZHOU C,CHEN G,HUANG Y,et al.Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL):a randomised,open-label,multicentre,phase 3 trial£ÛJ£Ý.Lancet Respir Med,2021,9(3):305-314.
£Û16£Ý ZHANG L,WANG Z,FANG J,et al.Final overall survival data of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study£ÛJ£Ý.Lung Cancer,2022,171:56-60.
£Û17£Ý RODRIGUEZ-ABREU D,POWELL SF,HOCHMAIR MJ,et al.Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC:protocol-specified final analysis from KEYNOTE-189£ÛJ£Ý.Ann Oncol,2021,32(7):881-895.
£Û18£Ý LU S,WANG J,YU Y,et al.Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304):A randomized phase 3 trial£ÛJ£Ý.J Thorac Oncol,2021,16(9):1512-1522.
£Û19£Ý TANIGUCHI Y,SHIMOKAWA T,TAKIGUCHI Y,et al.A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naive non-small cell lung cancer:TORG1630£ÛJ£Ý.Clin Cancer Res,2022,28(20):4402-4409.
£Û20£Ý ÖìÎŽÝ,ÖìºÀ»ª,ÁõÓêÌÒ,µÈ.³ÌÐòÐÔËÀÍöµ°°×1/³ÌÐòÐÔËÀÍöµ°°×ÅäÌå1ÒÖÖƼÁÖÎÁÆÍíÆÚ·ÇСϸ°û·Î°©µÄÁÆЧ¼°ÁÆЧºÍÔ¤ºóÔ¤²â±êÖ¾ÎïµÄÕæʵÊÀ½çÑо¿£ÛJ£Ý.ÖлªÖ×ÁöÔÓÖ¾,2022,44(05):416-424. ZHU WJ,ZHU HH,LIU YT,et al.Real-world study of efficacy and efficacy and prognostic predictive markers of patients with meastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors£ÛJ£Ý.Chinese Journal of Oncology,2022,44(05):416-424.
£Û21£Ý VARAYATHU H,SARATHY V,THOMAS BE,et al.Translational relevance of baseline peripheral blood biomarkers to assess the efficacy of anti-programmed cell death 1 use in solid malignancies£ÛJ£Ý.J Cancer Res Ther,2021,17(1):114-121.
£Û22£Ý ¿×Ïééª,ÕÅÈã,ËÎÐÀÐÂ,µÈ.·ÇСϸ°û·Î°©»¼Õ߷ξ²ÂöѪѭ»·Ö×Áöϸ°ûÊýÁ¿¼°³ÌÐòÐÔËÀÍöÊÜÌåÅäÌå-1±í´ïÓëÔ¤ºóµÄ¹Øϵ£ÛJ£Ý.ÖлªÊµÓÃÕï¶ÏÓëÖÎÁÆÔÓÖ¾,2021,35(11):1100-1103. KONG XN,ZHANG R,SONG XX,et al.Correlations of pulmonary venous circulating tumor cells and programmed death receptor ligand-1 with prognosis of patients with non-small cell lung cancer£ÛJ£Ý.Journal of Chinese Practical Diagnosis and Therapy,2021,35(11):1100-1103.
£Û23£Ý BHALLA S,DOROSHOW DB,HIRSCH FR.Predictive biomarkers for immune checkpoint inhibitors in advanced non-small cell lung cancer:current status and future directions£ÛJ£Ý.Cancer J,2020,26(6):507-516.
£Û24£Ý ÐìС·å,´÷ºêÓî,Çǽ¨±ø,µÈ.ÍâÖÜѪNLRºÍPLRÆÀ¹ÀÍíÆÚ·ÇСϸ°û·Î°©Ò»Ïߺ¬²¬Ë«Ò©»¯ÁÆÁÆЧºÍÔ¤ºóµÄ¼ÛÖµ£ÛJ£Ý.ÏÖ´úÖ×Áöҽѧ,2020,28(15):2627-2631. XU XF,DAI HY,QIAO JB,et al.Effect of the NLR and PLR on the response of first line platinum -based chemotherapy and the prognosis in advanced NSCLC£ÛJ£Ý.Modern Oncology,2020,28(15):2627-2631.
£Û25£Ý AN HJ,CHON HJ,KIM C.Peripheral blood-based biomarkers for immune checkpoint inhibitors£ÛJ£Ý.Int J Mol Sci,2021,22(17):9414.
£Û26£Ý HUANG H,LI L,LUO W,et al.Lymphocyte percentage as a valuable predictor of prognosis in lung cancer£ÛJ£Ý.J Cell Mol Med,2022,26(7):1918-1931.
£Û27£Ý MATSUBARA T,TAKAMORI S,HARATAKE N,et al.Identification of the best prognostic marker among immunonutritional parameters using serum C-reactive protein and albumin in non-small cell lung cancer£ÛJ£Ý.Ann Surg Oncol,2021,28(6):3046-3054.
£Û28£Ý ZHANG X,XING P,HAO X,et al.Clinical value of serum albumin level in patients with non-small cell lung cancer and anaplastic lymphoma kinase (ALK) rearrangement£ÛJ£Ý.Ann Palliat Med,2021,10(12):12403-12411.
£Û29£Ý PENG L,WANG Y,LIU F,et al.Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors£ÛJ£Ý.Cancer Immunol Immunother,2020,69(9):1813-1822.
£Û30£Ý SUNG M,JANG WS,KIM HR,et al.Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio,C-reactive protein,and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy£ÛJ£Ý.Transl Lung Cancer Res,2023,12(7):1506-1516.

Memo

Memo:

ºÓÄÏÊ¡¿Æ¼¼¹¥¹ØÏîÄ¿£¨±àºÅ£ºLHGJ20220998£©

Common functions

Last Update: 1900-01-01